For the twelve months ended Oct 2, 2026, STAAR Surgical Company reported $328.27M of revenue and $530.0K of net income.
STAA revenue was $83.41M in fiscal Q3 2026 (ended Oct 2, 2026), down 12.0% from a year earlier and down 10.8% from the prior quarter. For the full fiscal 2025 it was $239.44M, down 23.7% from fiscal 2024. Compound annual growth was +7.9% over 5 years and +12.0% over 10 years. It rose in 8 of the last 10 fiscal years.
STAA net income was $5.58M in fiscal Q3 2026 (ended Oct 2, 2026), down 37.2% from a year earlier and down 30.8% from the prior quarter. For the full fiscal 2025 it was -$80.45M, compared with -$20.21M in fiscal 2024.
STAA diluted EPS was $0.11 in fiscal Q3 2026 (ended Oct 2, 2026), down 38.9% from a year earlier and down 31.3% from the prior quarter. For the full fiscal 2025 it was -$1.62, compared with -$0.41 in fiscal 2024.
STAA free cash flow was $26.38M in fiscal Q3 2026 (ended Oct 2, 2026), up about 15-fold from a year earlier and up 37.4% from the prior quarter. For the full fiscal 2025 it was -$40.05M, compared with -$7.67M in fiscal 2024.
| Line item | Jan 2, 2026 | Dec 27, 2024 | Dec 29, 2023 | Dec 30, 2022 | Dec 31, 2021 | Jan 1, 2021 | Jan 3, 2020 | Dec 28, 2018 | Dec 29, 2017 | Dec 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $239.44M | $313.90M | $322.42M | $239.44M | $230.47M | $163.46M | $150.19M | $123.95M | $90.61M | $82.43M |
| Cost of revenue | $57.02M | $74.32M | $69.76M | $61.01M | $51.84M | $45.10M | $38.23M | $32.44M | $26.33M | $24.06M |
| Gross profit | $182.42M | $239.58M | $252.65M | $223.38M | $178.64M | $118.36M | $111.95M | $91.51M | $64.28M | $58.37M |
| Research and development | $40.05M | $45.32M | $40.48M | $35.98M | $33.86M | $31.92M | $25.30M | $22.03M | $20.04M | $20.67M |
| Selling, general and admin | $274.13M | $252.19M | $224.55M | $179.58M | $145.30M | $111.59M | $100.10M | $84.92M | $67.91M | $71.02M |
| Operating income | -$91.71M | -$12.61M | $28.10M | $43.80M | $33.34M | $6.77M | $11.85M | $6.59M | -$3.63M | -$12.65M |
| Interest expense | - | - | - | - | - | - | - | - | $112.0K | $112.0K |
| Pre-tax income | -$82.26M | -$9.05M | $33.70M | $45.55M | $31.30M | $8.27M | $13.03M | $6.64M | -$2.30M | -$12.44M |
| Income tax | -$1.81M | $11.16M | $12.35M | $5.89M | $3.79M | $2.35M | -$1.02M | $1.67M | -$157.0K | -$315.0K |
| Net income | -$80.45M | -$20.21M | $21.35M | $39.66M | $27.51M | $5.91M | $14.05M | $4.97M | -$2.14M | -$12.13M |
| EPS, basic | -$1.62 | -$0.41 | $0.44 | $0.83 | $0.58 | $0.13 | $0.32 | $0.12 | -$0.05 | -$0.30 |
| EPS, diluted | -$1.62 | -$0.41 | $0.43 | $0.80 | $0.56 | $0.12 | $0.30 | $0.11 | -$0.05 | -$0.30 |
| Diluted shares | 49.6M | 49.1M | 49.4M | 49.4M | 49.5M | 48.0M | 46.9M | 45.3M | 41.0M | 40.3M |
| Line item | Jan 2, 2026 | Dec 27, 2024 | Dec 29, 2023 | Dec 30, 2022 | Dec 31, 2021 | Jan 1, 2021 | Jan 3, 2020 | Dec 28, 2018 | Dec 29, 2017 | Dec 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $153.15M | $144.16M | $183.04M | $86.48M | $199.71M | $152.45M | $119.97M | $104.00M | $18.64M | $14.12M |
| Short-term investments | $34.39M | $86.33M | $37.69M | $125.16M | - | - | - | - | - | - |
| Receivables | $50.06M | $77.90M | $94.70M | $62.45M | $43.53M | $35.23M | $31.00M | $25.95M | $17.85M | $16.34M |
| Current assets | $311.55M | $367.94M | $365.27M | $311.72M | $271.41M | $216.42M | $174.67M | $151.57M | $53.89M | $49.52M |
| Goodwill | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M |
| Total assets | $451.68M | $509.52M | $488.69M | $418.82M | $345.78M | $257.42M | $207.52M | $167.34M | $67.93M | $65.48M |
| Current liabilities | $68.50M | $70.31M | $65.04M | $51.72M | $48.80M | $41.24M | $34.48M | $27.73M | $19.09M | $21.07M |
| Total liabilities | $107.49M | $112.19M | $102.74M | $82.71M | $87.22M | $60.19M | $47.64M | $34.91M | $25.00M | $27.57M |
| Shareholders' equity | $344.18M | $397.33M | $385.95M | $336.11M | $261.57M | $197.22M | $159.88M | $132.43M | $42.94M | $37.91M |
| Line item | Jan 2, 2026 | Dec 27, 2024 | Dec 29, 2023 | Dec 30, 2022 | Dec 31, 2021 | Jan 1, 2021 | Jan 3, 2020 | Dec 28, 2018 | Dec 29, 2017 | Dec 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$34.23M | $15.72M | $14.59M | $35.72M | $43.96M | $20.95M | $25.80M | $12.77M | $2.85M | $1.05M |
| Capital expenditures | $5.82M | $23.39M | $18.19M | $18.11M | $13.64M | $8.40M | $10.10M | $2.25M | $1.05M | $3.21M |
| Free cash flow | -$40.05M | -$7.67M | -$3.59M | $17.61M | $30.32M | $12.55M | $15.70M | $10.52M | $1.81M | -$2.16M |
| Investing cash flow | $46.34M | -$59.22M | $74.35M | -$156.38M | -$13.64M | -$8.40M | -$10.18M | -$2.25M | -$1.05M | -$3.21M |
| Financing cash flow | -$4.55M | $5.72M | $7.42M | $8.30M | $17.79M | $19.57M | $149.0K | $74.64M | $2.44M | $2.95M |
| Share repurchases | $6.46M | - | - | - | - | - | - | - | - | - |
| Stock-based compensation | $30.59M | $27.21M | $23.52M | $20.37M | $14.61M | $12.15M | $10.55M | $6.76M | $3.16M | $8.56M |
| Line item | Jan 2, 2026 | Dec 27, 2024 | Dec 29, 2023 | Dec 30, 2022 | Dec 31, 2021 | Jan 1, 2021 | Jan 3, 2020 | Dec 28, 2018 | Dec 29, 2017 | Dec 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -23.7% | -2.6% | 34.7% | 3.9% | 41.0% | 8.8% | 21.2% | 36.8% | 9.9% | 6.9% |
| Net income growth, YoY | - | - | -46.2% | 44.2% | 365.3% | -57.9% | 182.8% | - | - | - |
| EPS growth, YoY | - | - | -46.3% | 42.9% | 366.7% | -60.0% | 172.7% | - | - | - |
| Gross margin | 76.2% | 76.3% | 78.4% | 93.3% | 77.5% | 72.4% | 74.5% | 73.8% | 70.9% | 70.8% |
| Operating margin | -38.3% | -4.0% | 8.7% | 18.3% | 14.5% | 4.1% | 7.9% | 5.3% | -4.0% | -15.4% |
| Net margin | -33.6% | -6.4% | 6.6% | 16.6% | 11.9% | 3.6% | 9.4% | 4.0% | -2.4% | -14.7% |
| Free cash flow margin | -16.7% | -2.4% | -1.1% | 7.4% | 13.2% | 7.7% | 10.5% | 8.5% | 2.0% | -2.6% |
| Return on equity | -23.4% | -5.1% | 5.5% | 11.8% | 10.5% | 3.0% | 8.8% | 3.8% | -5.0% | -32.0% |
| Return on assets | -17.8% | -4.0% | 4.4% | 9.5% | 8.0% | 2.3% | 6.8% | 3.0% | -3.1% | -18.5% |
| Current ratio | 4.55 | 5.23 | 5.62 | 6.03 | 5.56 | 5.25 | 5.07 | 5.47 | 2.82 | 2.35 |
| Line item | Oct 2, 2026 | Jul 3, 2026 | Apr 3, 2026 | Jan 2, 2026 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 27, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 29, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.41M | $93.53M | $93.52M | $57.80M | $94.73M | $44.32M | $42.59M | $48.95M | $88.59M | $99.00M | $77.36M | $76.27M |
| Cost of revenue | $24.28M | $23.81M | $24.66M | $14.06M | $16.86M | $11.52M | $14.58M | $17.30M | $20.10M | $20.59M | $16.32M | $15.55M |
| Gross profit | $59.13M | $69.73M | $68.86M | $43.74M | $77.88M | $32.80M | $28.00M | $31.65M | $68.49M | $78.41M | $61.03M | $60.73M |
| Research and development | $10.46M | $9.94M | $9.93M | $9.24M | $9.21M | $10.26M | $11.34M | $9.77M | $12.25M | $11.87M | $13.38M | $6.94M |
| Selling, general and admin | $53.68M | $59.63M | $60.88M | $66.58M | $59.38M | $62.76M | $85.41M | $59.56M | $62.80M | $66.51M | $63.32M | $50.32M |
| Operating income | $5.46M | $10.10M | $7.98M | -$22.84M | $18.49M | -$29.96M | -$57.40M | -$27.91M | $5.68M | $11.90M | -$2.28M | $10.40M |
| Pre-tax income | $6.98M | $11.02M | $8.22M | -$20.65M | $18.79M | -$25.91M | -$54.49M | -$30.33M | $13.16M | $10.33M | -$2.21M | $13.74M |
| Income tax | $1.41M | $2.97M | $3.01M | -$2.34M | $9.91M | -$9.10M | -$275.0K | $3.89M | $3.18M | $2.96M | $1.13M | $5.98M |
| Net income | $5.58M | $8.06M | $5.21M | -$18.31M | $8.88M | -$16.81M | -$54.21M | -$34.23M | $9.98M | $7.38M | -$3.34M | $7.76M |
| EPS, basic | $0.11 | $0.16 | $0.10 | -$0.36 | $0.18 | -$0.34 | -$1.10 | -$0.69 | $0.20 | $0.15 | -$0.07 | $0.15 |
| EPS, diluted | $0.11 | $0.16 | $0.10 | -$0.36 | $0.18 | -$0.34 | -$1.10 | -$0.69 | $0.20 | $0.15 | -$0.07 | $0.16 |
| Diluted shares | 51.4M | 51.5M | 50.9M | - | 50.5M | 49.5M | 49.3M | - | 49.7M | 49.8M | 48.9M | - |
| Line item | Oct 2, 2026 | Jul 3, 2026 | Apr 3, 2026 | Jan 2, 2026 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 27, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 29, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $133.61M | $148.58M | $131.86M | $153.15M | $176.16M | $167.13M | $173.11M | $144.16M | $164.00M | $192.78M | $224.02M | $183.04M |
| Short-term investments | $72.80M | $32.91M | $32.02M | $34.39M | $16.50M | $22.75M | $49.65M | $86.33M | $71.95M | $42.42M | $21.13M | $37.69M |
| Receivables | $86.53M | $98.47M | $81.17M | $50.06M | $60.10M | $34.44M | $39.95M | $77.90M | $104.51M | $93.80M | $64.60M | $94.70M |
| Current assets | $353.43M | $342.35M | $312.40M | $311.55M | $321.21M | $292.79M | $326.50M | $367.94M | $397.11M | $383.82M | $365.71M | $365.27M |
| Goodwill | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M |
| Total assets | $485.16M | $475.20M | $451.12M | $451.68M | $456.36M | $437.78M | $457.36M | $509.52M | $537.59M | $512.75M | $492.54M | $488.69M |
| Current liabilities | $75.54M | $73.39M | $60.99M | $68.50M | $61.64M | $59.23M | $68.36M | $70.31M | $66.34M | $66.17M | $62.67M | $65.04M |
| Total liabilities | $109.03M | $109.81M | $98.75M | $107.49M | $102.58M | $101.21M | $107.39M | $112.19M | $109.47M | $103.64M | $99.75M | $102.74M |
| Shareholders' equity | $376.13M | $365.40M | $352.37M | $344.18M | $353.78M | $336.57M | $349.97M | $397.33M | $428.12M | $409.10M | $392.79M | $385.95M |
| Line item | Oct 2, 2026 | Jul 3, 2026 | Apr 3, 2026 | Jan 2, 2026 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 27, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 29, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $27.32M | $19.69M | -$21.70M | -$3.91M | $2.67M | -$27.25M | -$5.73M | $642.0K | $3.82M | -$10.41M | $21.68M | $31.97M |
| Capital expenditures | $935.0K | $494.0K | $443.0K | $1.68M | $883.0K | $1.79M | $1.47M | $5.72M | $6.23M | $6.24M | $5.20M | $3.09M |
| Free cash flow | $26.38M | $19.20M | -$22.14M | -$5.59M | $1.78M | -$29.04M | -$7.20M | -$5.08M | -$2.42M | -$16.65M | $16.48M | $28.88M |
| Investing cash flow | -$40.67M | -$1.37M | $2.15M | -$19.41M | $5.28M | $25.12M | $35.35M | -$19.50M | -$35.24M | -$20.67M | $16.19M | $22.40M |
| Financing cash flow | -$1.32M | -$1.50M | -$1.69M | -$50.0K | $983.0K | -$4.54M | -$948.0K | -$110.0K | $1.61M | $163.0K | $4.06M | $367.0K |
| Share repurchases | - | - | - | $0 | $1.98M | - | - | - | - | - | - | - |
| Stock-based compensation | $5.52M | $6.56M | $4.82M | $8.61M | $8.16M | $7.80M | $6.01M | $4.67M | $7.16M | $9.04M | $6.34M | $182.0K |
| Line item | Oct 2, 2026 | Jul 3, 2026 | Apr 3, 2026 | Jan 2, 2026 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 27, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 29, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -12.0% | 111.0% | 119.6% | 18.1% | 6.9% | -55.2% | -44.9% | -35.8% | 10.3% | 7.3% | 5.2% | 299.4% |
| Net income growth, YoY | -37.2% | - | - | - | -11.0% | - | - | - | 107.2% | 21.7% | - | 14.7% |
| EPS growth, YoY | -38.9% | - | - | - | -10.0% | - | - | - | 100.0% | 25.0% | - | 14.3% |
| Gross margin | 70.9% | 74.5% | 73.6% | 75.7% | 82.2% | 74.0% | 65.8% | 64.7% | 77.3% | 79.2% | 78.9% | 79.6% |
| Operating margin | 6.5% | 10.8% | 8.5% | -39.5% | 19.5% | -67.6% | -134.8% | -57.0% | 6.4% | 12.0% | -2.9% | 13.6% |
| Net margin | 6.7% | 8.6% | 5.6% | -31.7% | 9.4% | -37.9% | -127.3% | -69.9% | 11.3% | 7.5% | -4.3% | 10.2% |
| Free cash flow margin | 31.6% | 20.5% | -23.7% | -9.7% | 1.9% | -65.5% | -16.9% | -10.4% | -2.7% | -16.8% | 21.3% | 37.9% |
| Current ratio | 4.68 | 4.66 | 5.12 | 4.55 | 5.21 | 4.94 | 4.78 | 5.23 | 5.99 | 5.80 | 5.84 | 5.62 |
Source: XBRL data STAAR Surgical Company files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| STAA | $328.27M | +42.4% | $530.0K | 0.2% | $1.27B |
| ALC | $10.40B | +4.9% | $980.00M | 9.4% | $37.45B |
| COO | $4.24B | +4.7% | $570.30M | 13.5% | $11.86B |
| BLCO | $5.42B | +8.9% | -$111.00M | -2.0% | $7.15B |
| WRBY | $934.66M | +9.9% | $7.47M | 0.8% | $3.15B |
| EYE | $2.03B | +7.8% | $50.29M | 2.5% | $1.41B |
| RXST | $121.83M | -14.3% | -$53.36M | -43.8% | $190.1M |
| LUCY | $3.41M | +72.5% | -$7.69M | -225.3% | $7.2M |